

## Causes of Death and Comorbidities in Patients with COVID-19

Sefer Elezkurtaj<sup>1</sup>, Selina Greuel<sup>1</sup>, Jana Ihlow<sup>1</sup>, Edward Michaelis<sup>1</sup>, Philip Bischoff<sup>1</sup>, Catarina Alisa Kunze<sup>1</sup>, Bruno Valentin Sinn<sup>1</sup>, Manuela Gerhold<sup>1</sup>, Kathrin Hauptmann<sup>1</sup>, Barbara Ingold-Heppner<sup>2</sup>, Florian Miller<sup>3</sup>, Hermann Herbst<sup>3</sup>, Victor Max Corman<sup>4</sup>, Hubert Martin<sup>5</sup>, Helena Radbruch<sup>5</sup>, Frank L. Heppner<sup>5,6,7,8</sup> and David Horst<sup>1,\*</sup>

1 Institute of Pathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany

2 Institute of Pathology, DRK Kliniken Berlin, Berlin, Germany

3 Institute of Pathology, Vivantes GmbH, Berlin, Germany

4 Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, and German Centre for Infection Research, 10117 Berlin, Germany.

5 Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany

6 Berlin Institute of Health (BIH), 10117 Berlin, Germany

7 Cluster of Excellence, NeuroCure, Charitéplatz 1, 10117 Berlin, Germany

8 German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany

**Running Title:** Cause of death in COVID-19

### \* Corresponding author

David Horst

Institute of Pathology, Charité – Universitätsmedizin Berlin

Charitéplatz 1, 10117 Berlin

Email: david.horst@charite.de

Phone: +49-30-450-536002

Fax: +49-30-450-536900

**Keywords:** COVID-19, SARS-CoV-2, corona, cause of death, comorbidity, autopsy

**Conflicts of interest:** None.

## **ABSTRACT**

Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has caused several hundreds of thousands of deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of comorbidities to death yet is missing. Here, we report autopsy findings on causes of death and comorbidities of 26 decedents that had clinically presented with severe COVID-19. We found that septic shock and multi organ failure was the most common immediate cause of death, often due to suppurative pulmonary infection. Respiratory failure due to diffuse alveolar damage presented as the most immediate cause of death in fewer cases. Several comorbidities, such as hypertension, ischemic heart disease, and obesity were present in the vast majority of patients. Our findings reveal that causes of death were directly related to COVID-19 in the majority of decedents, while they appear not to be an immediate result of preexisting health conditions and comorbidities. We therefore suggest that the majority of patients had died of COVID-19 with only contributory implications of preexisting health conditions to the mechanism of death.

## INTRODUCTION

More than 7.9 million confirmed cases of coronavirus disease 2019 (COVID-19) and more than 434 thousand associated deaths have been counted around the globe by June 15, 2020<sup>1</sup>. COVID-19 is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel and highly contagious coronavirus strain that mostly spreads through respiratory droplets and that has first been identified in Wuhan, China<sup>2</sup>.

Some SARS-CoV-2 infections are asymptomatic while most cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat<sup>3,4</sup>. However, a significant number of patients with COVID-19 develops critical illness and requires intensive care with mechanical ventilation or extracorporeal membrane oxygenation<sup>5,6</sup>. Especially in these cases, the disease may ultimately be fatal<sup>7</sup>. While raw numbers of deaths suggest overall COVID-19 case-fatality rates of more than 5 %<sup>1</sup>, infection-fatality rates probably are lower and may range around 0.3-0.5 %<sup>8</sup>.

The risk of death from COVID-19 strongly depends on age and previous health conditions. Older patients and those with chronic comorbidities, such as cardiovascular disease, hypertension, diabetes, and pulmonary disease, are much more prone to critical and fatal disease outcomes<sup>4,9</sup>. These associations may contribute to an uncertainty to what extent COVID-19 or preexisting health conditions determined the time of a patient's death. Detailed information on the causality and mechanism of death, as well as the spectrum of comorbidities in cases with fatal outcome that will allow accurate assessment of the hazardous nature of COVID-19 yet is missing.

Autopsies are the gold standard for the analysis of medical conditions and causes of death. Few reports described damage to several organs due to COVID-19 on the morphological level. However, while one study reported fatal pulmonary thromboembolism in few cases<sup>10</sup>, systematic information on immediate and underlying causes of death are scarce. Here, we present data on clinical and autptic causes of death and comorbidities of 26 patients that had died after SARS-CoV-2 infection and COVID-19 in Berlin, Germany. Our findings reveal that causes of death were directly related to COVID-19 in most cases and not an immediate consequence of preexisting health conditions and comorbidities, i.e. these patients – despite often suffering from severe health conditions – would not have died in the absence of a SARS-CoV-2 infection at the given time point.

## **METHODS**

### **Study design**

26 cases of patients that had died after COVID-19 disease were included. In all cases, SARS-CoV-2 infection was confirmed by PCR testing of material from nasal and pharyngeal swabs. In 24 cases, patients had been treated at Charité – Universitätsmedizin Berlin, while two were referred from Vivantes – Netzwerk für Gesundheit GmbH and DRK Kliniken Berlin. Autopsies were performed on the legal basis of §1 SRegG BE of the autopsy act of Berlin and §25(4) of the German Infection Protection Act. This study was approved by the Ethics Committee of the Charité (EA 1/144/13 and EA2/066/20) as well as by the Charité-BIH COVID-19 research board and was in compliance with the Declaration of Helsinki. Clinical information on comorbidities and pre-existing conditions was obtained from patient files and clinical death certificates.

### **Autopsy procedure**

External examination, complete autopsy and tissue sampling were performed in 26 patients with COVID-19 according to the traditional technique by opening all luminal structures and lamellar incisions of all parenchymatous organs. According to recent recommendations for the performance of autopsies in cases of suspected COVID-19, safety precautions including FFP2-masks, protective suits and cut resistant gloves were applied for all autopsies<sup>11</sup>. For histopathology, representative tissue samples of all organs were fixed in 4 % buffered formalin, dehydrated, paraffin embedded and sectioned with a thickness of 4 µm. Paraffin sections were stained with hematoxylin and eosin (HE), periodic acid Schiff's reaction (PAS), Van Gieson's elastic stain, Prussian blue stain and Kongo-red stain. At least two pathologists examined all slides by light microscopy.

### **Statistical analysis**

Data collection and statistical analysis were done with IBM SPSS Statistics, Version 23 (IBM, NY, USA). Age at death was presented as median with interquartile range (IQR) to account for deviations from normal distribution. Categorical variables were summarized as counts and percentages. Median time to death was analyzed using the Kaplan-Meier method.

## RESULTS

### Clinical presentation and causes of death in COVID-19 decedents

We analyzed 26 cases of patients that died after COVID-19 disease and that were autopsied at the Institute of Pathology of the Charité university hospital in Berlin. In all cases, SARS-CoV-2 infection was confirmed by PCR testing. Of the decedents, 17 were male and 9 were female. One of the decedents was of Black ethnicity, while 25 were Caucasians. The median age at death was 70 years (IQR: 61.8 - 78.3, range: 30 to 92 years), and the time from onset of COVID-19 symptoms to death ranged from 5 to 51 days, with a median of 26 days. Additional clinical information on the course of the disease was available in all cases. Prior to death, all patients had presented with COVID-19 related lung disease. Signs of respiratory failure were most prevalent with 88.5 %, while in 57.7 % patients had signs of bacterial pneumonia. Furthermore, pulmonary thromboembolism was reported in 23.1 % of the cases with clinical evidence of deep venous thrombosis in two patients (7.7 %). Due to the severity of lung damage, patient care warranted invasive ventilation in 76.9 %, prone positioning in 53.8 %, and extracorporeal membrane oxygenation in 30.8 % (Table 1). Aside from lung involvement, acute renal failure was the second most prevalent organ failure and hemodialysis was necessary in 69.2 % of the patients. Furthermore, half of the patients presented with multi-organ failure, while acute liver failure was reported in 30.8 %. These findings indicated severe and complex courses of COVID-19 in these patients. An overview of the clinical characteristics is given in Table 1.

To learn about clinical causes of death, we assessed legal death certificates of the 26 decedents. Most frequent immediate causes of death, documented in 19 cases (73.1 %), were infection related, and included sepsis, septic shock, or sepsis-related multi-organ failure in 16 cases (61.5 %), bacterial infections in two cases (7.7 %), and viral pneumonia in one case (3.8 %). Second most common were respiration-related causes of death, documented as respiratory insufficiency, hypoxia, or acute respiratory distress syndrome (ARDS) in four cases (15.4 %). Further individual immediate causes of death were pulmonary embolism and cardiovascular failure (3.8 % each).

In addition, clinical death certificates provided information on conditions leading to immediate causes of death and death-related underlying disease (Table 1). Here, pulmonary disease in 22 decedents (84.6 %) was the most frequently documented condition leading to cause of death, which included pneumonia or viral pneumonia in 14 cases (53.8 %), and ARDS in eight cases (30.8 %). Importantly, when jointly considering conditions leading to cause of death and underlying disease, COVID-19, confirmed or suspected SARS-CoV-2 infection was documented

in a total of 23 cases (88.5 %), and thus in the vast majority of deceased patients. Other underlying diseases that were deemed clinically relevant for death included cancer in two cases (7.7 %), and individual cases of alcohol abuse, renal failure, COPD, or GvHD. Collectively, these data indicated that, from a clinical perspective, COVID-19 and infection-related disease were major contributors to patients' death in the majority of cases.

### **Clinical information on comorbidities**

Clinical records also contained information on chronic comorbidities and further relevant health conditions. The median number of chronic comorbidities in these cases was four, and ranged from three to eight (Table 1). Arterial hypertension was the most prevalent chronic condition in the decedents (65.4 %), followed by obesity (38.5 %), chronic ischemic heart disease (34.6 %), atrial fibrillation (26.9 %), and chronic obstructive pulmonary disease (23.1 %). Vascular conditions were specified as atherosclerosis (7.7 %) and cerebrovascular disease (15.4 %). Of all patients, 15.4 % had diabetes type II, and chronic renal failure was noticed in 11.5 % of decedents. Active or non-active nicotine abuse was noted in 5 patients (19.2 %) and alcohol abuse in 3 patients (11.5 %). Further details are available from Table 1. These data suggested severe chronic comorbidities and health conditions in the majority of patients that had died after COVID-19.

### **Causes of death determined at autopsy in decedents with COVID-19**

In order to investigate causes of death directly, we performed full body autopsies including histopathological workup on all 26 decedents. Based on assessment of pathological disease mechanisms and referring to clinical documentations of death, we defined immediate causes of death, conditions leading to cause of death, and underlying causes (Table 2). As the most common immediate cause of death, we found septic shock and/or multi-organ failure in 8 patients (30.8 %), followed by suppurative pulmonary infections in five patients (19.2 %), including bacterial pneumonia with or without abscess formation, as well as infarct necrosis with signs of purulent bacterial superinfection. Right ventricular congestive heart failure or decompensation as immediate cause of death was present in four patients (15.4 %). In five patients (19.2 %), respiratory failure or diffuse alveolar damage was the immediate cause of death, with severe lung damage implicating highly restricted gas exchange. Four more cases presented with either deadly pulmonary thromboembolism, severe bronchial aspiration, gastrointestinal bleeding, or signs of left ventricular heart failure (3.8 % each).

We then determined conditions leading to these immediate causes of death (Table 2). We found that COVID-19 or SARS-CoV-2 infection most prevalently preceded the immediate cause of death in ten cases (38.5 %), followed by bacterial pneumonia with or without abscess formation in six cases (23.1 %), pulmonary bleeding in two cases (7.7 %), and arterial thrombosis or thromboembolism also in two cases (7.7 %). In addition, we found individual cases with invasive pulmonary mycosis or gastric peptic ulcer as conditions leading to cause of death (3.8 % each). Of note, in three cases (11.5 %) we did not find pathologies that would qualify for an intermediate between underlying and immediate cause of death.

Next, we identified underlying causes of death, i.e. diseases that initiated the events resulting in death (Table 2). For this, we considered all autopsy findings and the clinical history to determine the underlying disease that would causally explain conditions leading to cause of death and immediate causes of death in all cases. We determined COVID-19 pneumonia as underlying cause of death in the majority of decedents (53.8%). Of note, when considering COVID-19 or SARS-CoV-2 infection as underlying cause of death or condition leading to cause of death, this applied to a total of 24 cases (92.3 %). Preexisting lung emphysema, pulmonary hypertension, and chronic right ventricular insufficiency were considered as diseases underlying cause of death in 26.9 %. In two cases (7.7 %), cardiovascular disease, and in two further cases (7.7 %), malignant tumors or consequences of tumor therapy were considered as underlying disease. Collectively, our findings demonstrate that septic organ failure, pneumonia, respiratory insufficiency, and right ventricular heart failure due to COVID-19 were the most frequent pathological mechanisms of death in these patients.

### **Comorbidities found by autopsy in COVID-19 decedents**

To learn about other relevant disease conditions in patients that died after SARS-CoV-2 infection, we determined the presence and extent of comorbidities by autopsy (Table 2). Generalized atherosclerosis was present in all but one case (96.2%), and was mild in 9 (34.6 %), moderate in 3 (11.5 %) and severe in 13 cases (50 %). Similarly, coronary artery disease was seen in all but two cases (92.3 %), and was mild in 8 (30.8 %), moderate in 4 (15.4 %) and severe in 11 decedents (42.3 %). Furthermore, we noticed preexisting emphysema of the lungs in almost half of the cases (46.2 %), and pulmonary artery sclerosis as a sign of pulmonary hypertension in 11 cases (42.3 %). Other comorbidities included myocardial hypertrophy (65.4%), hepatosteatorosis (11.5%) and liver fibrosis (7.7%). In two cases (7.7 %), we defined COVID-19 or SARS-CoV-2 as comorbidity, since we did not observe a direct contribution of this

infection to the mechanism of death. These findings demonstrated a high prevalence of cardiovascular and pulmonary comorbidities in patients that had died after COVID-19.



## DISCUSSION

Here, we present data on causes of death and comorbidities in patients that had died after a severe course of COVID-19. These patients had reached a median age of 70 years, which in line with previous reports indicates increased risks for fatal COVID-19 outcome with older age<sup>12,13</sup>. Clinical records showed that in the majority of cases, respiratory insufficiency was a dominating symptom, while the most frequent clinical cause of death was sepsis and thus infection related. In line with these findings, we found by autopsy that sepsis caused by purulent bacterial lung infection was the most frequent cause of death, while, in some cases, we observed deadly respiratory insufficiency due to diffuse alveolar damage. These findings suggested that SARS-CoV-2 infection could directly cause lethal lung damage. However, death due to pulmonary bacterial superinfection and sepsis appeared to be a more common causal chain of events that may significantly endanger patients with severe COVID-19-related lung damage. We hypothesize that such causality may be even more prevalent in clinical settings where respiratory insufficiency is manageable by mechanical ventilation or extracorporeal oxygenation.

A recent study showed high frequencies of fatal pulmonary thromboembolism in patients that had died of COVID-19<sup>10</sup>. Deep venous thrombosis was identified as the likely thromboembolic source. In line with these findings, pulmonary thromboembolism was diagnosed in almost every fourth of our patients during the clinical course of the disease. However, we found that pulmonary thromboembolism was an immediate cause of death or a condition leading to cause of death in two cases only, which suggests that in other cases hypercoagulability may have been effectively controlled by anti-coagulant treatment. Nevertheless, hypercoagulability appears to be an important, severe and potentially fatal aspect of COVID-19<sup>14,15</sup>. Furthermore, peripheral microthrombosis in multiple organ systems has been reported<sup>16</sup>, which may cause severe organ damage also in patients that survive COVID-19. It therefore remains to be determined by prospective clinical studies, if anti-coagulation reduces the risk of COVID-19 related death, and to what extent this affects the risk of organ damage in COVID-19 survivors.

The majority of deceased patients in our study had diagnosed comorbidities that with arterial hypertension, chronic kidney or heart disease, and chronic pulmonary disease most frequently affected the cardiovascular and respiratory system. By autopsy, we confirmed these clinical diagnoses, since we found their pathological correlates that included general and coronary atherosclerosis, cardiac hypertrophy, and pulmonary emphysema amongst others. In addition, we found a high prevalence of lifestyle risk factors, such as obesity, alcohol consumption, and nicotine abuse. These findings are in agreement with previous studies and imply that patients

with preexisting chronic health conditions or lifestyle risk factors are at an increased risk for fatal outcome of COVID-19<sup>17,18</sup>. However, considering both the high frequency of these comorbidities and the relatively high age of patients that died after SARS-CoV-2 infection, this led to a reasonable debate about the extent to which preexisting health conditions or COVID-19 determined the time of death<sup>19</sup>, and our data may further inform about this issue. We found that sepsis due to lung infections and respiratory insufficiency were the most frequent immediate causes of death. However, our autopsy series included no single case of immediate deadly ischemic heart disease or stroke, which are the most common causes of death worldwide<sup>20</sup>, and for which the majority of comorbidities as well as the mentioned life style risk factors that we found were strongly predisposing<sup>21</sup>. This indicates that the immediate causes of death appear not to be caused directly from the observed comorbidities but instead were directly linked to lung damage initiated by SARS-CoV-2 infection in most cases. Our data therefore suggest that in the majority of our cases with severe and fatal COVID-19, patients had died of this disease, although in the presence of multiple preexisting health conditions. These findings also support the idea that patients who died of COVID-19 appear to have lost considerable lifetime, independent of their age, as reported by others<sup>19</sup>.

A limitation of our study is the relatively small sample size. Furthermore, patients included in this study had reached a median age of 70 years, which mirrors reported age distributions of inpatient non-survivors in Wuhan<sup>12</sup>, and data from a recent autopsy report<sup>16</sup>, but is lower than suggested by other epidemiologic data from Italy on COVID-19 decedents<sup>22</sup>. While regional factors may influence age distribution, this discrepancy also suggests a case selection bias, and we speculate this may reflect which patients were hospitalized and therefore received most intense therapeutic measures. The interpretation of autopsy results and conclusions on health impacts of COVID-19 therefore requires careful consideration of the study population.

## **ACKNOWLEDGEMENTS**

We are indebted to Anistan Sebastiampillai, Juliane Plaschke and Francisca Egelhofer for excellent technical assistance and helpful advice. The authors declare no conflicts of interest.

## **AUTHORS CONTRIBUTIONS**

S.E., S.G., J.I., E.M., P.B., C.K., B.I.H., H.H., H.M., H.R., F.H. and D.H. performed autopsies, histopathology and clinical workup. V.M.C. made viral RT-qPCR workups. D.H. supervised the study. All authors analyzed the data, wrote, revised and approved the manuscript.

## REFERENCES

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020; **20**(5): 533-534; e-pub ahead of print 2020/02/23; doi 10.1016/S1473-3099(20)30120-1.
2. Organization WH. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020>. Accessed 15.06.2020.
3. Control ECfDPa. COVID-19 situation update for the EU/EEA and the UK, as of 13 June 2020. <https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea>. Accessed 15.06.2020.
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; e-pub ahead of print 2020/02/25; doi 10.1001/jama.2020.2648.
5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A *et al.* Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; e-pub ahead of print 2020/04/07; doi 10.1001/jama.2020.5394.
6. Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G *et al.* Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. *ASAIO J* 2020; **66**(5): 472-474; e-pub ahead of print 2020/04/04; doi 10.1097/MAT.0000000000001173.
7. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**(5): 475-481; e-pub ahead of print 2020/02/28; doi 10.1016/S2213-2600(20)30079-5.
8. Streeck H, Schulte B, Kümmerer BM, Richter E, T. H, Fuhrmann C *et al.* Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. In:2020.
9. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med* 2020; e-pub ahead of print 2020/05/02; doi 10.1056/NEJMoa2007621.
10. Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A *et al.* Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Ann Intern Med* 2020; e-pub ahead of print 2020/05/07; doi 10.7326/M20-2003.
11. Prevention CfDCa. Collection and Submission of Postmortem Specimens from Deceased Persons with Known or Suspected COVID-19 - Interim Guidance. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html>. Accessed 15.06.2020.
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-1062; e-pub ahead of print 2020/03/15; doi 10.1016/S0140-6736(20)30566-3.
13. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019

- Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; e-pub ahead of print 2020/03/14; doi 10.1001/jamainternmed.2020.0994.
14. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; **191**: 145-147; e-pub ahead of print 2020/04/16; doi 10.1016/j.thromres.2020.04.013.
  15. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X *et al.* High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020; **46**(6): 1089-1098; e-pub ahead of print 2020/05/06; doi 10.1007/s00134-020-06062-x.
  16. Bryce C, Grimes Z, Pujadas E, Ahuja S. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. <https://www.medrxiv.org/content/10.1101/2020.05.18.20099960v1>. Accessed 15.06.2020 (2020).
  17. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y *et al.* Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; **369**: m1966; e-pub ahead of print 2020/05/24; doi 10.1136/bmj.m1966.
  18. Team CC-R. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(13): 382-386; e-pub ahead of print 2020/04/03; doi 10.15585/mmwr.mm6913e2.
  19. Hanlon P, Chadwick F, Shah A, Wood R. COVID-19 – exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study. <https://wellcomeopenresearch.org/articles/5-75> (2020).
  20. Organization WH. The top 10 causes of death. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed 15.06.2020.
  21. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM *et al.* General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008; **117**(6): 743-753; e-pub ahead of print 2008/01/24; doi 10.1161/CIRCULATIONAHA.107.699579.
  22. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA* 2020; e-pub ahead of print 2020/03/24; doi 10.1001/jama.2020.4683.

## TABLES

**Table 1:** Clinical causes of death and documented comorbidities in hospitalized patients with COVID-19

Case	Age [years]	Gender	Symptoms to death [days]	Immediate cause of death	Condition leading to cause of death	Underlying cause	Comorbidities and further relevant conditions
1	54	M	12	Hypoxia	ARDS	COVID-19	Active smoking, COPD, HIV-infection, obesity, ventricular fibrillation
2	62	M	12	Sepsis	Pneumonia	COVID-19 infection	Diabetes II, heart failure, hypertension, obesity, OSAS
3	45	F	18	Septic MODS	SARS-CoV-2 pneumonia	Viral pneumonia	Asthma, COPD, hypertension, mesenterial infarction
4	71	M	29	Septic MODS	ARDS	COVID-19 pneumonia	Asthma, atrial fibrillation, hypertension, sinus node arrest
5	79	F	15	Septic shock	ARDS	COVID-19	Hypertension, ischaemic heart disease, obesity, OSAS
6	90	F	n/a	Respiratory failure	COVID-19 pneumonia	SARS-Cov-2 infection	Atrial fibrillation, chronic renal failure, COPD, dementia, hypertension, ischaemic heart disease, liver cirrhosis
7	79	M	26	Respiratory failure	ARDS	COVID-19 pneumonia	Hemiplegia, Pulmonary embolism
8	79	F	13	Cardiovascular failure	Pneumonia	COVID-19	Dementia, diabetes II, hypertension, ischaemic heart disease, rheumatoid arthritis, stroke
9	68	M	34	Sepsis	ARDS	COVID-19	Alcohol abuse, heart failure, obesity
10	61	M	21	Septic shock	ARDS	COVID-19 pneumonia	Active smoking, atrial fibrillation, heart failure, hypertension, ischaemic heart failure, obesity
11	68	F	37	Septic shock	Pneumonia with bacterial superinfection	COVID-19 pneumonia	COPD, hypertension, hyperthyreosis, obesity
12	68	M	5	Pulmonary embolism	Tumor thrombophilia	Squamous cell carcinoma lung	COPD, COVID-19 pneumonia, heart failure, HIV-infection, ischaemic heart disease, stroke, chronic renal failure
13	76	M	14	Septic shock	Pneumonia	COVID-19	Active smoking, heart failure, hypertension, ischaemic heart disease, obesity

**Table 1** (continued)

Case	Age [years]	Gender	Symptoms to death [days]	Immediate cause of death	Condition leading to cause of death	Underlying cause	Comorbidities and further relevant conditions
14	56	F	24	Septic shock	ARDS	COVID-19 pneumonia	Diabetes II, hypertension, obesity
15	92	M	28	Bacterial superinfection	-	COVID-19	Atrial fibrillation, dementia, ischaemic heart disease
16	62	M	28	Respiratory failure	COVID-19 pneumonia	Alcohol abuse	Dementia, hypertension, stroke, recent fracture (femur 03/2020)
17	67	F	26	Sepsis	COVID-19 pneumonia	COPD	Atrial fibrillation, chronic intracerebral bleeding, COPD, hypertension, rheumatoid arthritis, stroke
18	81	M	n/a	Sepsis	COVID-19 pneumonia	Acute renal failure	Atrial fibrillation, diabetes II, hypertension, hyperthyreosis, stroke
19	78	F	n/a	Viral pneumonia	Suspected COVID-19	Small cell lung cancer right lower pulmonary lobe	Atrial fibrillation, hypertension, metastazied lung cancer (brain, liver, bone), obesity, therapy-induced pneumonitis
20	74	M	51	ARDS	Pneumonia	COVID-19	Atrial fibrillation, hypertension, ischaemic heart disease, obesity
21	76	M	43	Sepsis	Pneumonia	COVID-19 infection	Pulmonary embolism
22	30	F	21	Septic shock with MODS	Sepsis	GvHD intestine	COVID-19, history of chemoradiotherapy for Ewing sarcoma
23	77	M	42	Septic shock	ARDS	COVID-19	Hypertension
24	69	M	40	Septic shock	Pneumogen sepsis	COVID-19 pneumonia	Hypertension
25	57	M	34	Staphylococcus pneumonia	Viral pneumonia	COVID-19	-
26	74	M	35	MODS	Sepsis	Pneumonia	Aortic valve stenosis, ischaemic heart disease

Abbreviations: male (M), female (F), not applicable (n/a), coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO), chronic obstructive pulmonary disease (COPD), human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), obstructive sleep apnea syndrome (OSAS), multiple organ dysfunction syndrome (MODS), graft-versus-host disease (GvHD)

**Table 2:** Causes of death and comorbidities in Patients with COVID-19 as determined by autopsy

Case	Age [years]	Gender	Symptoms to death [days]	Immediate cause of death	Condition leading to cause of death	Underlying cause	Comorbidities and further relevant conditions
1	54	M	12	Respiratory failure	COVID-19	Lung emphysema	Atherosclerosis, coronary artery sclerosis, diverticulosis of the sigmoid colon, myocardial hypertrophy, pulmonary embolism,
2	62	M	12	Pulmonary embolism	-	COVID-19 pneumonia	Atherosclerosis, cardiomegaly, coronary artery sclerosis, hepatomegaly, myocardial hypertrophy, severe obesity
3	45	F	18	Septic MODS	Disseminated arterial thrombosis	COVID-19 pneumonia	Atherosclerosis, coronary artery sclerosis
4	71	M	29	Respiratory failure	Diffuse alveolar damage	COVID-19 pneumonia	Atherosclerosis, cardiomegaly, coronary artery sclerosis, myocardial hypertrophy
5	79	F	15	Abscess-forming (bacterial) pneumonia	COVID-19 pneumonia	Cor pulmonale	Atherosclerosis, cardiac amyloidosis, coronary artery sclerosis, hepatomegaly, hepatosteatorosis, myocardial hypertrophy, obesity °III
6	90	F	n/a	Right ventricular heart failure	COVID-19 pneumonia	Pulmonary emphysema and chronic bronchitis	Atherosclerosis, coronary artery sclerosis, end-stage atrophic kidney, liver fibrosis, myocardial hypertrophy
7	79	M	26	Right ventricular heart failure	COVID-19 pneumonia	Pulmonary emphysema, pulmonary artery sclerosis	Atherosclerosis, coronary artery sclerosis, myocardial hypertrophy
8	79	F	13	Bronchial aspiration	COVID-19 pneumonia with peripheral pulmonary embolism	Chronic right ventricular heart failure	Atherosclerosis, coronary artery sclerosis, myocardial hypertrophy, struma colloidis
9	68	M	34	Right cardiac failure	Diffuse pulmonary bleeding and pulmonary vascular thrombosis	COVID-19 pneumonia	Atherosclerosis, coronary artery sclerosis, liver infarction



**Table 2** (continued)

Case	Age [years]	Gender	Symptoms to death [days]	Immediate cause of death	Condition leading to cause of death	Underlying cause	Comorbidities and further relevant conditions
10	61	M	21	Right cardiac failure	Pulmonary edema, diffuse pulmonary bleeding	COVID-19 pneumonia	Atherosclerosis, coronary artery sclerosis, myocardial hypertrophy, herpes simplex tracheobronchitis, obesity °III, pulmonary arterial sclerosis, severe atherosclerosis
11	68	F	37	Septic shock	Focally abscess-forming pneumonia	COVID-19 pneumonia	Atherosclerosis, cholesteatosis, COPD, coronary artery sclerosis, hepatosteatosi, myocardial hypertrophy, obesity°II, struma colloides
12	68	M	5	Upper GI bleeding	Peptic ulcer		Atherosclerosis, COPD, coronary artery sclerosis, COVID-19 pneumonia, myocardial hypertrophy, NSCLC, upper gastrointestinal bleeding
13	76	M	14	Diffuse alveolar damage	COVID-19	Chronic ischemic cardiomyopathy	Abdominal aortic aneurysm, atherosclerosis, hepatosteatosi
14	56	F	24	Septic shock	Pneumonia	Covid-19 pneumonia	Atherosclerosis, coagulopathy, coronary artery sclerosis, myocardial hypertrophy
15	92	M	28	Respiratory failure	Pneumonia	Covid-19 pneumonia	Atherosclerosis, coronary artery sclerosis, hepatosplenomegaly, ischemic cardiomyopathy
16	62	M	28	Pneumonia	COVID-19 pneumonia	Pulmonary emphysema	Atherosclerosis, cholestasi, coronary artery sclerosis
17	67	F	26	Hemorrhagic pneumonia	COVID-19 pneumonia	Pulmonary emphysema	Atherosclerosis, coronary artery sclerosis, liver fibrosis, lymphadenopathy, myocardial hypertrophy, splenomegaly
18	81	M	n/a	Left ventricular heart failure	COVID-19 pneumonia	Atherosclerosis	Abdominal aortic aneurysm with thrombosis, atherosclerosis, cardiac amyloidosis, coronary artery sclerosis, myocardial hypertrophy, renal anemic infarct
19	78	F	n/a	Diffuse alveolar damage	SARS-CoV-2 infection	Metastatic SCLC (hepatic, adrenal)	Atherosclerosis, coronary artery sclerosis

**Table 2** (continued)

Case	Age [years]	Gender	Symptoms to death [days]	Immediate cause of death	Condition leading to cause of death	Underlying cause	Comorbidities and further relevant conditions
20	74	M	51	Septic MODS	Abscess-forming pneumonia	COVID-19 pneumonia	Atherosclerosis, cardiac amyloidosis, coronary artery sclerosis, ischemic cardiomyopathy, myocardial hypertrophy, pulmonary emphysema
21	76	M	43	Infected pulmonary infarction	Pulmonary embolism	COVID-19 pneumonia	Atherosclerosis, coronary artery sclerosis
22	30	F	21	Septic shock	Invasive pulmonary mycosis, intestinal GvHD	History of chemoradiotherapy for Ewing sarcoma and history of allo-HSCT for secondary MDS	Lymphocytic myocarditis, SARS-CoV-2 infection
23	77	M	42	MODS	Recurrent sepsis (clinical information)	COVID-19 pneumonia	Atherosclerosis, benign prostatic hyperplasia, cholesteatosis, coronary artery sclerosis, hepatomegaly, nodular goiter, struma multinodosa, urolithiasis,
24	69	M	40	Septic MODS	Abscess-forming pneumonia	COVID-19 pneumonia	Atherosclerosis, benign prostatic hyperplasia, endocarditis of the tricuspid valve, myocardial hypertrophy
25	57	M	34	Septic MODS	Abscess-forming pneumonia	COVID-19 pneumonia	Atherosclerosis, coronary artery sclerosis, myocardial hypertrophy, thrombotic varicocele of the left testicle
26	74	M	35	Recurrent pneumonia	-	COVID-19 pneumonia	Aortic valve prosthesis, atherosclerosis, coronary artery sclerosis, myocardial hypertrophy, pulmonary emphysema

Abbreviations: male (M), female (F), not applicable (n/a), coronavirus disease 2019 (COVID-19), chronic obstructive pulmonary disease (COPD), severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), multiple organ dysfunction syndrome (MODS), non small cell lung cancer (NSCLC), squamous cell lung carcinoma (SCLC), gastrointestinal tract (GI), graft-versus-host disease (GvHD), allogeneic hematopoietic stem cell transplantation (allo-HSCT), myelodysplastic syndrome (MDS)